Drug Profile
Research programme: respiratory syncytial virus therapeutics - Alnylam/Merck
Alternative Names: ALN RSV02Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Cubist Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Respiratory syncytial virus infections
Most Recent Events
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
- 07 Jan 2011 Alnylam Pharmaceuticals and Cubist Pharmaceuticals put the paediatric Respiratory syncytial virus therapeutics programme on hold (Inhalation)
- 27 Nov 2009 Preclinical trials in Respiratory syncytial virus infections in USA (Inhalation)